Medicago named Early Stage Company of the Year by BIOTECanada

    - Company to receive Gold Leaf Award at BIO 2009 -

    QUEBEC CITY, May 13 /CNW/ - Medicago Inc. (TSX-V: MDG), a biotechnology
company focused on developing highly effective and affordable vaccines based
on proprietary manufacturing technologies and Virus-Like Particles (VLPs),
today announced it has been selected to receive the Gold Leaf Award from
BIOTECanada for "Early Stage Company of the Year". Medicago will be presented
with this distinguished award on May 19, 2009 at the 2009 BIO International
Convention in Atlanta, USA. The award is given annually to a company that has
distinguished itself from its peers with demonstrated technology innovation
milestone achievements and financial success.
    "This leading firm is a stellar example of Canadian innovative thinking,
partnership potential, and research and development expertise," said
BIOTECanada President and CEO, Peter Brenders. "Once commercialized, its
products will make a significant contribution to Canada's economy."
    "We are honoured to have received this prestigious award from
BIOTECanada," said Andy Sheldon, President and CEO of Medicago. "We are at an
important stage of development with our first VLP vaccine entering Phase I
clinical trials later this year. This award recognizes the outstanding
contribution that Medicago's employees have made to the development of our
technology and achievement of corporate objectives."

    About Medicago

    Medicago is committed to provide highly effective and affordable vaccines
based on proprietary Virus-Like Particle (VLP) and manufacturing technologies.
Medicago is developing VLP vaccines to protect against H5N1 pandemic
influenza, using a transient expression system which produces recombinant
vaccine antigens in non-transgenic plants. This technology has potential to
offer advantages of speed and cost over competitive technologies. It could
deliver a vaccine for testing in about a month after the identification and
reception of genetic sequences from a pandemic strain. This production time
frame has the potential to allow vaccination of the population before the
first wave of a pandemic strikes and to supply large volumes of vaccine
antigens to the world market. Additional information about Medicago is
available at

    Forward Looking Statements

    This press release contains forward-looking statements which reflect
Medicago's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. Medicago disclaims any obligation to
update these forward-looking statements.

    Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.

For further information:

For further information: Contact: Medicago, Inc., Andy Sheldon,
President and CEO, (418) 658-9393; Medicago Inc., Arianna Vanin, Director,
Investor Relations, (514) 796-3993

Organization Profile

Medicago Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890